Cover Page



Universiteit Leiden




The handle http://hdl.handle.net/1887/35283 holds various files of this Leiden University dissertation

Author: Charehbili, Ayoub

Title: Optimising preoperative systemic therapy for breast cancer

Issue Date: 2015-09-16



Lay-out: Ayoub Charehbili Cover design: Ayoub Charehbili

Printed by: Gildeprint Drukkerijen, The Netherlands

Optimising preoperative systemic therapy for breast cancer Thesis, Leiden University Medical Center, the Netherlands 2015.

 $\ensuremath{^{\odot}}$ Ayoub Charehbili, the Netherlands 2015.

ISBN: 978-94-6233-019-1

The printing of this thesis was made possible by the departments of Medical Oncology and Surgery of the Leiden University Medical Center, Boehringer Ingelheim, Chipsoft, Philips, Novartis, Pfizer and Galephar.

Optimising preoperative systemic therapy for breast cancer

Proefschrift

ter verkrijging van de graad van Doctor aan de Universiteit Leiden, op gezag van Rector Magnificus prof. Mr. C.J.J.M. Stolker, volgens besluit van het College voor Promoties te verdedigen op 16 september 2015 klokke 16:15

door

Ayoub Charehbili

Rotterdam, 1990.

Promotiecommissie

Promotores: Prof. dr. C.J.H. van de Velde

Prof. dr. J.W.R. Nortier

Copromotor: dr. J.R. Kroep

Overige leden: dr. G.J. Liefers

prof.dr. S.C. Linn, Netherlands Cancer Institute

prof. dr. H. Putter

prof dr. V.T.H.B.M. Smit

dr. N.A.T. Hamdy

Contents

Introduction	1			
Chapter 1	General introduction and outline of this thesis			
Part I				
Chapter 2	Can zoledronic acid be beneficial for promoting tumor response in breast cancer patients treated with neoadjuvant chemotherapy?			
Chapter 3	Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial			
Chapter 4	Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: a meta-analysis of randomized trials			
Chapter 5	Accuracy of MRI for treatment response assessment after taxane- and anthracyclin- based neoadjuvant chemotherapy in HER2-negative breast cancer	58		
Chapter 6	Vitamin D (25-OH D3) status and pathological response to neo-adjuvant chemotherapy in stage II/III breast cancer	70		
Part II				
Chapter 7	Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review	82		
Chapter 8	Efficacy of six month neoadjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer patients			
Chapter 9	Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients	116		
Summary &	Discussion			
Chapter 10	Summary, general discussion and future perspectives	126		